Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium

Hormone and Metabolic Research

Volumn 42, Issue 1, 2010, Pages 61-64

  Matuszczyk, A ^a   Petersenn, S ^a   Voigt, W ^b   Kegel, T ^b   Dralle, H ^b   Schmoll, H J ^b   Bockisch, A ^a   Mann, K ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Effect of therapy; Endocrine tumor; Malignant disease; Neoplasm

Indexed keywords

CISPLATIN; CLEMASTINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; GRANISETRON; PACLITAXEL; RANITIDINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLICULAR CARCINOMA; HAIR LOSS; HISTOLOGY; HUMAN; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PAPILLARY CARCINOMA; PERIPHERAL NEUROPATHY; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SKIN DEFECT; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; CARCINOMA, MEDULLARY; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; THYROID NEOPLASMS;

EID: 73949123850     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1238294     Document Type: Article

References (31)

1. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006 154 787-803
2. Mann K, Möller LC, Bockisch A, Quadbeck B, Schmid KW, Janssen OE. Chemotherapie beim Schilddrüsenkarzinom. Onkologe 2005 11 78-86
3. Matuszczyk A, Petersenn S, Bockisch A, Gorges R, Sheu SY, Veit P, Mann K. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008 40 210-213
4. 18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 2003 30 22-25
5. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000 27 490-496
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New Guidelines to Evaluate the Response to Treatment in Solid Tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 205-216
7. 18F]-fluorodeoxyglucose and Positron Emissions Tomography: Review and 1999 EORTC Recommendations. Eur J Cancer 1999 35 1773-1782
8. Hoskin PJ, Harmer C. Chemotherapy for thyroid cancer. Radiother Oncol 1987 10 187-194
9. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986 70 405-407 (Pubitemid 16130224)
10. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985 56 2155-2160
11. Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, Beretta G. Phase I and Preliminary Phase II Evaluation of Adriamycin. Cancer Res 1970 30 2572-2582
12. Samonigg H, Hossfeld DK, Spehn J, Fill H, Leb G. Aclarubicin in advanced thyroid cancer: A phase II study. Eur J Cancer Clin Oncol 1988 24 1271-1275
13. Scherübl H, Raue F, Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 1990 116 21-23
14. Ekman ET, Lundell G, Tennvall J, Wallin G. Chemotherapy and multimodality treatment in thyroid carcinoma. Otolaryngol Clin North Am 1990 23 523-527
15. Schlumberger M, Parmentier C. Phase II evaluation of mitoxantrone in advanced non anaplastic thyroid cancer. Bull Cancer 1989 76 403-406
16. Suzumura K, Koike A, Naruse T, Matsumoto K, Nagata H, Kojima T, Kanemitsu T, Katoh K. Antitumor effect of UFT against differentiated thyroid cancer. Gan To Kagaku Ryoho 1994 21 2485-2489
17. Zlock DW, Greenspan FS, Clark OH, Higgins CB. Octreotide therapy in advanced thyroid cancer. Thyroid 1994 4 427-431
18. De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, Casara D, Zorat, Fiorentino MV. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 1991 14 475-480
19. Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol 2005 131 585-590
20. Ain KB, Tofiq S, Taylor KD. Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 1996 81 3650-3653
21. Kaczirek K, Schindl M, Weinhäusel A, Scheuba C, Passler C, Prager G, Raderer M, Hamilton G, Mittlböck M, Siegl V, Pfragner R, Niederle B. Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. J Clin Endocrinol Metab 2004 89 2397-2401
22. Yang HL, Pan JX, Sun L, Yeung SC. p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003 88 763-772
23. Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, Nelkin BD. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 2007 92 4712-4718
24. Skinner MA, Safford SD, Freemerman AJ. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Res 2003 23 3601-3606
25. Henderson YC, Fredrick MJ, Clayman GL. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors. Arch Otolaryngol Head Neck Surg 2007 133 810-815
26. Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007 17 663-670
27. Kundra P, Burman KD. Thyroid cancer molecular signaling pathways and use of targeted therapy. Endocrinol Metab Clin North Am 2007 36 839-853
28. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007 25 884-896
29. Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch Otolaryngol Head Neck Surg 2007 133 1022-1027
30. Vidal M, Wells S, Ryan A, Cagan R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res 2005 65 3538-3541
31. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 2004 145 1031-1038